Zacks Investment Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$33.8M Buy
96,082
+748
+0.8% +$267K 0.27% 95
2025
Q4
$31.2M Buy
95,334
+2,103
+2% +$667K 0.25% 106
2025
Q3
$26.3M Sell
93,231
-19
-0% -$5.51K 0.21% 117
2025
Q2
$26M Sell
93,250
-1,283
-1% -$363K 0.22% 114
2025
Q1
$29.5M Buy
94,533
+3,141
+3% +$928K 0.28% 102
2024
Q4
$23.8M Sell
91,392
-7,227
-7% -$2.14M 0.22% 112
2024
Q3
$31.8M Buy
+98,619
New +$32.3M 0.28% 96
2024
Q2
Sell
-84,438
Closed -$24M 626
2024
Q1
$24M Buy
84,438
+4,784
+6% +$1.4M 0.26% 98
2023
Q4
$22.9M Buy
79,654
+486
+0.6% +$132K 0.28% 97
2023
Q3
$21.3M Buy
79,168
+927
+1% +$231K 0.28% 93
2023
Q2
$17.4M Buy
78,241
+975
+1% +$226K 0.22% 109
2023
Q1
$18.7M Sell
77,266
-16,302
-17% -$4M 0.25% 98
2022
Q4
$24.6M Buy
93,568
+3,655
+4% +$980K 0.34% 77
2022
Q3
$20.3M Buy
89,913
+1,274
+1% +$309K 0.32% 82
2022
Q2
$21.6M Buy
88,639
+20,107
+29% +$4.93M 0.33% 80
2022
Q1
$16.6M Buy
68,532
+3,015
+5% +$693K 0.23% 102
2021
Q4
$14.7M Buy
65,517
+1,100
+2% +$232K 0.21% 119
2021
Q3
$13.7M Buy
64,417
+315
+0.5% +$72.5K 0.22% 109
2021
Q2
$15.6M Sell
64,102
-843
-1% -$207K 0.25% 103
2021
Q1
$16.2M Sell
64,945
-161,000
-71% -$38.4M 0.29% 95
2020
Q4
$51.9M Sell
225,945
-17,955
-7% -$4.14M 0.96% 32
2020
Q3
$62M Sell
243,900
-18,613
-7% -$4.61M 1.26% 17
2020
Q2
$61.9M Buy
262,513
+2,635
+1% +$601K 1.36% 17
2020
Q1
$52.7M Sell
259,878
-2,625
-1% -$573K 1.29% 19
2019
Q4
$63.3M Buy
262,503
+8,828
+3% +$1.95M 1.19% 24
2019
Q3
$49.1M Buy
253,675
+4,402
+2% +$845K 0.98% 36
2019
Q2
$45.9M Buy
249,273
+2,563
+1% +$459K 0.94% 35
2019
Q1
$46.9M Sell
246,710
-33,006
-12% -$6.3M 1.01% 26
2018
Q4
$54.5M Sell
279,716
-1,511
-0.5% -$295K 1.31% 16
2018
Q3
$58.3M Buy
281,227
+3,682
+1% +$726K 1.22% 20
2018
Q2
$51.2M Buy
277,545
+2,192
+0.8% +$388K 1.11% 22
2018
Q1
$46.9M Buy
275,353
+1,901
+0.7% +$349K 1.04% 27
2017
Q4
$47.6M Buy
273,452
+4,573
+2% +$809K 1.04% 27
2017
Q3
$50.1M Buy
268,879
+2,148
+0.8% +$381K 1.17% 24
2017
Q2
$45.9M Buy
266,731
+165,839
+164% +$27M 1.14% 26
2017
Q1
$16.6M Buy
100,892
+10,134
+11% +$1.68M 0.42% 73
2016
Q4
$13.3M Sell
90,758
-18,258
-17% -$2.75M 0.38% 73
2016
Q3
$18.2M Sell
109,016
-964
-0.9% -$163K 0.51% 62
2016
Q2
$16.7M Sell
109,980
-323
-0.3% -$50.2K 0.51% 57
2016
Q1
$16.5M Sell
110,303
-16,600
-13% -$2.47M 0.52% 59
2015
Q4
$20.6M Sell
126,903
-54
-0% -$8.49K 0.67% 45
2015
Q3
$17.6M Buy
126,957
+1,784
+1% +$281K 0.61% 49
2015
Q2
$19.2M Buy
125,173
+2,963
+2% +$475K 0.61% 54
2015
Q1
$19.5M Buy
122,210
+12,659
+12% +$1.99M 0.62% 53
2014
Q4
$17.4M Buy
109,551
+14,488
+15% +$2.26M 0.57% 56
2014
Q3
$13.4M Buy
95,063
+23,865
+34% +$3.12M 0.47% 75
2014
Q2
$8.45M Sell
71,198
-20,403
-22% -$2.36M 0.3% 104
2014
Q1
$11.3M Buy
91,601
+3,716
+4% +$451K 0.42% 84
2013
Q4
$10M Sell
87,885
-18,599
-17% -$2.12M 0.4% 97
2013
Q3
$11.9M Sell
106,484
-8,063
-7% -$874K 0.52% 72
2013
Q2
$11.3M Buy
+114,547
New +$11.9M 0.52% 71

Other funds holding AMGN

Zacks Investment Management's AMGN Position: Q1 2026 in Review

Zacks Investment Management increased its Amgen (AMGN) stake by 0.78% in Q1 2026, buying an estimated $267K and bringing the position to 96,082 shares worth $33.8M. The position accounts for 0.27% of the portfolio, ranked #95.

Zacks Investment Management first reported a position in AMGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $63.3M in Q4 2019. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Zacks Investment Management held 96,082 shares of Amgen worth $33.8M as of Q1 2026.
  • Zacks Investment Management bought 748 Amgen shares in Q1 2026, an estimated $267K.
  • Amgen made up 0.27% of Zacks Investment Management's portfolio in Q1 2026, its #95 holding.
  • Zacks Investment Management first reported a position in Amgen in Q2 2013 and has held it in 51 quarters since.
  • Zacks Investment Management's Amgen position peaked at $63.3M in Q4 2019.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.